RxDoctor Payments Data

Osama Siddique, MD

Gastroenterology · Rocky Hill, CTNPI 1558746230

Payments from drug & device makers

$5,881in general payments, 2019–2025

Across 63 payments — averaging $93.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Olympus Corporation Of The Americas$1K
  • Ovesco Endoscopy USA, Inc.$786
  • Gilead$266
  • AbbVie$206
  • Pfizer$116
  • plus $465 from 10 others

What the payments were for

  • Travel & lodging$3,90466%
  • Food & beverage$1,97734%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,881 in reported general payments places this provider in the 60th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$70,996
Medicare patients
258
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$450,437
XeljanzTofacitinib Citrate26$232,726
Humira(Cf) PenAdalimumab14$95,248
CreonLipase/Protease/Amylase26$65,303
LinzessLinaclotide53$46,043
ZenpepLipase/Protease/Amylase16$31,884
MotegrityPrucalopride Succinate26$16,543
Dexlansoprazole DrDexlansoprazole32$14,134
VemlidyTenofovir Alafenamide11$14,024
NexiumEsomeprazole Magnesium11$13,628
Mesalamine17$7,480
TrulancePlecanatide12$6,480
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,200
Lubiprostone21$4,486
Pantoprazole Sodium244$4,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$46$450,43715 claims
PfizerXeljanz$116$232,72626 claims
AbbVieCreon, Linzess$206$111,34579 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$106$16,54326 claims
GileadVemlidy$266$14,02411 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$14$6,48012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Rocky Hill

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →